{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"161"},{"groupId":"OG001","value":"146"}]}],"title":"SAEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"324"},{"groupId":"OG001","value":"321"}]}],"title":"Other Non-serious AEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"52"}]}],"title":"Died"}],"denoms":[{"counts":[{"groupId":"OG000","value":"327"},{"groupId":"OG001","value":"329"}],"units":"Participants"}],"description":"Participants who died or who had clinically significant events defined as serious AEs (SAEs) and other non-serious AEs (regardless of causality). A summary of SAEs and other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module.","groups":[{"description":"8 mg/kg of ramucirumab (IMC-1121B) was administered by IV infusion on Days 1 and 15 in combination with 80 mg/m² paclitaxel administered by IV infusion on Days 1, 8, and 15 of a 28-day cycle.","id":"OG000","title":"Ramucirumab (IMC-1211B) Plus Paclitaxel"},{"description":"Placebo was administered by IV infusion on Days 1 and 15, in combination with 80 mg/m² paclitaxel administered on Days 1, 8, and 15 of a 28-day cycle.","id":"OG001","title":"Placebo Plus Paclitaxel"}],"paramType":"NUMBER","populationDescription":"All randomized participants who received at least 1 dose of study drug and based on the treatment each participant received.","reportingStatus":"POSTED","timeFrame":"Baseline up to 103 weeks and within 30 days of last dose of study drug","title":"Number of Participants With Serious and Other Non-serious Adverse Events (AE) and Who Died","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"participants"}